RxDoctor Payments Data

Farhan Fazal, MD

Psychiatry · Hazard, KYNPI 1912162611

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 88 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$380
  • Johnson & Johnson$298
  • Otsuka America Pharmaceutical, Inc.$203
  • Lundbeck LLC$168
  • E.r. Squibb & Sons, L.L.C.$86
  • Axsome Therapeutics, Inc.$76
  • plus $301 from 9 others

What the payments were for

  • Food & beverage$1,508100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,512 in reported general payments places this provider in the 70th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$51,544
Medicare patients
74
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate28$91,121
Risperdal ConstaRisperidone Microspheres31$35,704
LybalviOlanzapine/Samidorphan Malate11$11,260
Aripiprazole109$5,837
ZubsolvBuprenorphine Hcl/Naloxone Hcl21$5,691
Paliperidone ErPaliperidone11$5,123
Fluphenazine Hcl25$4,055
Quetiapine Fumarate220$3,238
Venlafaxine Hcl ErVenlafaxine Hcl188$2,944
Divalproex Sodium86$2,717
Haloperidol80$2,705
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl71$2,581
Trazodone Hcl134$1,725
Chlorpromazine Hcl15$1,523
Bupropion XlBupropion Hcl93$1,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$298$126,82559 claims
Alkermes, Inc.Lybalvi$380$11,26011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →